Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

Some oral anti-hyperglycemic drugs, including gliptins that inhibit dipeptidyl peptidase 4 (DPP4), have been linked to the increased risk of heart failure (HF) in type-2 diabetic patients. While the cardiovascular safety trial, TECOS, revealed no link between sitagliptin and the risk of HF, a substa...

Descripción completa

Detalles Bibliográficos
Autores principales: Koyani, Chintan N., Trummer, Christopher, Shrestha, Niroj, Scheruebel, Susanne, Bourgeois, Benjamin, Plastira, Ioanna, Kickmaier, Sandra, Sourij, Harald, Rainer, Peter P., Madl, Tobias, Sattler, Wolfgang, Pelzmann, Brigitte, Malle, Ernst, von Lewinski, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Physiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246635/
https://www.ncbi.nlm.nih.gov/pubmed/30487758
http://dx.doi.org/10.3389/fphys.2018.01622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6246635/
https://www.ncbi.nlm.nih.gov/pubmed/30487758
http://dx.doi.org/10.3389/fphys.2018.01622

Ejemplares similares